HCPCS Level II Q2043: Sipuleucel‑T Autologous Cell Immunotherapy, Per Infusion
HCPCS Level II code Q2043 describes administration of sipuleucel‑T consisting of a minimum of 50 million autologous CD54+ cells activated with PAP‑GM‑CSF, including leukapheresis and all preparatory procedures, billed per infusion; this represents a cellular immunotherapy service typically delivered in an outpatient infusion center or specialized oncology clinic and involves leukapheresis, cell processing, and subsequent infusion visits.
Customize your policy alerts
Sign up for hcpcs Q2043 policy alerts
Get alerted when payer policies referencing Q2043 are released or updated.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.